AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-12 (Canceled).

Claim 13 (Previously Presented): A method for treating Alzheimer's disease in a patient comprising administration to said patient of a composition containing a therapeutically effective amount of at least one beta-naphthoquinone derivative and a pharmaceutically acceptable carrier, wherein said beta-naphthoquinone derivative is selected among the group consisting of:

(i) compounds having the formula (I):

wherein R represents -NH-CO-NH2, -NH-CO-CH3, or -OH group,

(ii) glucuronide derivatives thereof having the formula (II):

wherein R is as indicated in (i), and (iii) addition salts thereof.

Claim 14 (Currently Amended): The method of claim 13, wherein said beta-naphthoguinone beta-naphthoquinone derivative is selected among the group consisting of the 1,2-naphthoquinone, 2-semicarbazone and the 1-(1-hydroxy,2-naphthyl)semicarbazide-1-β-O-gluco-pyranosiduronic acid.

Claim 15 (Previously Presented): A method for treating Parkinson's disease in a patient comprising administration to said patient of a composition containing a therapeutically effective amount of at least one beta-naphthoquinone derivative and a pharmaceutically acceptable carrier, wherein said beta-naphthoquinone derivative is selected among the group consisting of:

(i) compounds having the formula (I):

wherein R represents -NH-CO-NH2, -NH-CO-CH3, or -OH group,

(ii) glucuronide derivatives thereof having the formula (II):

wherein R is as indicated in (i), and

(iii) addition salts thereof.

Claim 16 (Currently Amended): The method of claim 15, wherein said beta-naphthoguinone beta-naphthoquinone derivative is selected among the group consisting of the 1,2-naphthoquinone, 2-semicarbazone and the 1-(1-hydroxy,2-naphthyl)semicarbazide-1-β-O-gluco-pyranosiduronic acid.